Complement 3 Glomerulopathy - Pipeline Insight, 2024

This “Complement 3 Glomerulopathy - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Complement 3 Glomerulopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Complement 3 Glomerulopathy Understanding

Complement 3 Glomerulopathy: Overview

Complement 3 glomerulopathy (C3G) is a rare kidney disease that has two forms: dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). Each is caused by genetic or acquired problems in controlling the body’s complement system, which helps fight infections. Genetic problems can be inherited or not inherited. The acquired complications arise during a person’s life. C3G can have a major impact on a person’s health. The signs and symptoms of DDD tend to appear earlier than those of C3GN (usually in adolescence). However, the signs and symptoms of either form of C3G may not begin until adulthood. People with C3G often have symptoms which are related to problems with the kidney and other parts of the body.

Complement 3 Glomerulopathy - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Complement 3 Glomerulopathy pipeline landscape is provided which includes the disease overview and Complement 3 Glomerulopathy treatment guidelines. The assessment part of the report embraces, in depth Complement 3 Glomerulopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Complement 3 Glomerulopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Complement 3 Glomerulopathy R&D. The therapies under development are focused on novel approaches to treat/improve Complement 3 Glomerulopathy.

Complement 3 Glomerulopathy Emerging Drugs Chapters

This segment of the Complement 3 Glomerulopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Complement 3 Glomerulopathy Emerging Drugs

Avacopan: Novartis Pharmaceuticals Avacopan is an orally-administered drug candidate that inhibits the complement C5a receptor, or C5aR, and is being developed for inflammatory and autoimmune diseases. Avacopan blocks the activity of complement C5a, a component of the complement system and the natural ligand for C5aR. It is in phase II stage of development to treat C3 Glomerulopathy
LNP 023: Novartis Pharmaceuticals Iptacopan is an investigational, first-in-class, orally administered factor B inhibitor of the alternative complement pathway, targeting one of the key drivers of these diseases9-11. It has the potential to become the first targeted therapy to delay progression to dialysis in C3G. It is in phase II stage of development to treat C3 Glomerulopathy

Complement 3 Glomerulopathy: Therapeutic Assessment

This segment of the report provides insights about the different Complement 3 Glomerulopathy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Complement 3 Glomerulopathy

There are approx. 3+ key companies which are developing the therapies for Complement 3 Glomerulopathy. The companies which have their Complement 3 Glomerulopathy drug candidates in the most advanced stage, i.e. phase II include, Novartis.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Complement 3 Glomerulopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Complement 3 Glomerulopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Complement 3 Glomerulopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Complement 3 Glomerulopathy drugs.

Complement 3 Glomerulopathy Report Insights

• Complement 3 Glomerulopathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Complement 3 Glomerulopathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Complement 3 Glomerulopathy drugs?
• How many Complement 3 Glomerulopathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Complement 3 Glomerulopathy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Complement 3 Glomerulopathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Complement 3 Glomerulopathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• ChemoCentryx
• Novartis Pharmaceuticals
• Omeros Corporation
• Apellis Pharmaceuticals

Key Products

• Avacopan
• Iptacopan
• OMS721
• APL-2

Please note: The report will be dispatched within 2-3 days